Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company entered a collaboration and license agreement in December 2011 to co-develop and co-commercialize ibrutinib. For medical information on IMBRUVICA (ibrutinib), please contact AbbVie Medical Information at https://www.abbviemedinfo.com or call 1-844-663-3742.